logo

Kiniksa Pharmaceuticals, Ltd. (KNSA)



Trade KNSA now with
  Date
  Headline
12/29/2021 4:21:38 PM Wedbush Is Raising Kiniksa Pharmaceuticals, Ltd. (KNSA) FY22 Estimate To -1.55 From -1.56
12/29/2021 4:21:14 PM Wedbush Is Increasing Kiniksa Pharmaceuticals, Ltd. (KNSA) FY21 Estimate To -2.26 From -2.27
12/29/2021 4:20:48 PM Wedbush Reiterates Kiniksa Pharmaceuticals, Ltd. (KNSA) At Outperform With $26 Price Target
12/28/2021 7:07:06 AM Kiniksa Says Phase 3 Trial Of Mavrilimumab In COVID-19-Related ARDS Fails To Meet Primary Endpoint
7/16/2020 7:40:20 AM Kiniksa: FDA Grants U.S. Orphan Drug Designation For Rilonacept For The Treatment Of Pericarditis
6/29/2020 7:23:16 AM Kiniksa Announces Positive Data From RHAPSODY, A Phase 3 Trial Of Rilonacept In Recurrent Pericarditis
6/8/2020 8:10:17 AM Kiniksa Reports 28-Day Clinical Outcomes Data From Mavrilimumab Treatment Protocol
5/14/2020 12:17:06 AM Kiniksa Pharma Prices Public Offering Of 2.4 Mln Class A Common Shares At $18.25/Shr
5/11/2020 7:45:07 AM Kiniksa Reports Data For Mavrilimumab And For Vixarelimab
3/19/2019 7:33:29 AM Wedbush Reiterates Kiniksa Pharmaceuticals, Ltd. (KNSA) At Outperform With $30 Price Target
12/12/2018 6:51:51 AM Wedbush Reiterates Kiniksa Pharmaceuticals, Ltd. (KNSA) At Outperform With $33 Up From $31 Price Target
9/17/2018 6:38:51 AM Wedbush Reiterates Kiniksa Pharmaceuticals, Ltd. (KNSA) At Outperform With $31 Price Target